GleamWall
中文EN

SLDB Solid Biosciences Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1707502 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-28.8%
TTM EPS YoY29.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-76.9%
ROA-64.9%
ROIC (approx.)-94.0%
Asset turnover—

Leverage & solvency

Liabilities / assets12.3%
Debt / equity0.00x
Current ratio11.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$43.59M$44.27M$46.14M$38.13M$38.86M$32.41M$30.91M$30.77M
SG&A expense$14.06M$13.12M$11.17M$11.27M$9.20M$9.28M$9.14M$9.13M
Operating income-$57.66M-$57.38M-$57.31M-$49.40M-$48.06M-$41.69M-$40.05M-$39.90M
Interest expense———$5,000-$336,000$60,000$68,000$75,000
Net income-$53.95M-$54.80M-$56.74M-$49.79M-$45.78M-$39.48M-$39.28M-$42.60M
EBITDA-$57.24M-$56.99M-$56.91M-$48.94M-$47.68M-$41.31M-$39.65M-$39.41M
EPS (basic)-0.36-0.38-0.52—-0.48-0.42-0.59—
EPS (diluted)-0.36-0.38-0.52—-0.48-0.42-0.59—
Weighted avg. shares (diluted)151.03M143.69M109.81M—94.42M94.14M66.34M—
Balance sheet
Cash & equivalents$125.97M$159.39M$297.10M$59.90M$61.36M$138.93M$210.63M$82.19M
Short-term investments$222.96M$218.28M$83.58M$127.95M$174.78M$129.18M$96.29M$68.69M
Current assets$365.19M$395.11M$396.79M$205.46M$244.85M$278.64M$313.41M$157.30M
PP&E, net$3.73M$3.96M$3.91M$4.17M$4.36M$4.32M$4.48M$4.75M
Total assets$389.90M$420.58M$422.89M$232.54M$273.91M$308.29M$343.90M$188.66M
Current liabilities$30.45M$28.58M$30.28M$33.47M$36.34M$29.85M$28.78M$30.26M
Total liabilities$47.79M$46.51M$48.76M$52.53M$55.97M$50.00M$49.44M$51.42M
Shareholders' equity$342.11M$374.07M$374.13M$180.01M$217.95M$258.29M$294.46M$137.25M
Shares outstanding111.56M105.13M98.39M78.97M77.88M77.60M77.49M40.47M
Cash flow statement
Operating cash flow-$45.55M-$52.59M-$47.23M-$53.55M-$33.47M-$37.41M-$31.85M-$29.64M
Capital expenditure$498,000$150,000$165,000$565,000$85,000$377,000$126,000$204,000
Free cash flow-$46.04M-$52.74M-$47.40M-$54.12M-$33.56M-$37.79M-$31.98M-$29.85M
Investing cash flow-$3.76M-$133.59M$44.76M$47.01M-$45.27M-$32.73M-$27.46M$38.57M
Financing cash flow$15.88M$48.47M$239.03M$5.14M$1.18M-$1.60M$189.73M$6.94M
Depreciation & amortization$416,000$391,000$395,000$467,000$376,000$386,000$407,000$488,000
Stock-based compensation$6.15M$5.62M$5.15M$6.50M$3.93M$3.15M$3.34M$3.82M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.